FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387641229> ?p ?o ?g. }

• W4387641229 endingPage "100507" @default.
• W4387641229 startingPage "100507" @default.
• W4387641229 abstract "Antiresorptive therapies are commonly utilized to mitigate and prevent skeletal-related-events in patients with metastatic osseous disease. However, limited data exists on the incidence or factors associated with prescription of antiresorptives or their effects on the incidence of pathologic fractures in patients with osseous metastatic disease. The aims of this study were to determine 1) the proportion of patients with osseous metastasis who receive antiresorptive therapy and sustain a pathologic fracture within 2-years of a new diagnosis, 2) factors associated with sustaining a pathologic fracture, and 3) factors are associated with the likelihood of receiving antiresorptive therapy. Between January 2010 and October 2021, 1,492,301 patients with a new diagnosis of osseous metastasis were captured in the Mariner dataset of the PearlDiver database. Patients were identified using International Classification of Disease (ICD) 10 codes for osseous metastasis. We excluded patients with a prior diagnosis of osseous metastasis and if they had less than two-years of follow-up. There were 696,459 patients (46.7 %) included for analysis. Of these patients, 63 % (N = 437,716) were over the age of 65, 46 % were women, and 5.6 % had Medicaid insurance. We identified patients who were prescribed antiresorptive therapy within 2-years of a new diagnosis of osseous metastasis. Cox proportional hazard ratio models were created to predict factors associated with 1) pathologic fracture and 2) receiving antiresorptive therapy within 2-years of a new diagnosis of osseous metastasis, respectively. The incidence of antiresorptive therapy prescription was 7.7 % in our cohort. The incidence of pathologic fracture within 2-years of a new diagnosis was 7.3 %. The risk of sustaining a pathologic fracture was higher for patients aged 35–44 (HR 1.27 [95 % CI 1.08–1.51]; p = 0.004), those with primary kidney cancer (HR 1.78 [95 % CI 1.71–1.85]; p < 0.001), p = 0.005), multiple myeloma (HR 2.49 [95 % CI 2.39–2.59]; p < 0.001), and Medicaid insurance (HR 1.17 [95 % CI 1.13–1.21]; p < 0.001). The risk of sustaining a pathologic fracture was lower for patients on antiresorptive therapy (HR 0.71 [95 % CI 0.66–0.83]; p < 0.001). Increasing age was an independent predictor for antiresorptive therapy prescription (HR 1.77–16.38, all p < 0.05). Male sex as well as diagnosis of primary prostate, lung, or kidney cancer and Medicaid insurance were negative predictors for antiresorptive prescription (HR 0.15–0.87, all p < 0.001). The utilization of antiresorptive therapy in patients with osseous metastases remains unacceptably low, with only 7.7% patients being prescribed these therapies, despite shown efficacy in reduction of pathologic fractures incidences. This study identified younger patients, males, and those diagnosed with primary prostate, kidney, and lung cancers to be at increased risk of not being prescribed antiresorptive therapy, suggesting possible bias in prescription patterns. Greater efforts are needed by providers who care for this vulnerable population to increase the utilization and reduce disparities of prescribing antiresorptive therapy." @default.
• W4387641229 created "2023-10-15" @default.
• W4387641229 creator A5033557427 @default.
• W4387641229 creator A5044696716 @default.
• W4387641229 creator A5059457931 @default.
• W4387641229 creator A5073766586 @default.
• W4387641229 creator A5089822117 @default.
• W4387641229 date "2023-12-01" @default.
• W4387641229 modified "2023-10-17" @default.
• W4387641229 title "The low and disproportionate utilization of antiresorptive therapy in patients with osseous metastasis" @default.
• W4387641229 cites W1911315648 @default.
• W4387641229 cites W1978292803 @default.
• W4387641229 cites W2011926580 @default.
• W4387641229 cites W2044016557 @default.
• W4387641229 cites W2067480481 @default.
• W4387641229 cites W2113701976 @default.
• W4387641229 cites W2136321395 @default.
• W4387641229 cites W2138067032 @default.
• W4387641229 cites W2149775776 @default.
• W4387641229 cites W2165011173 @default.
• W4387641229 cites W2416614764 @default.
• W4387641229 cites W2607028219 @default.
• W4387641229 cites W2806099717 @default.
• W4387641229 cites W2888671695 @default.
• W4387641229 cites W2902871270 @default.
• W4387641229 cites W3047188459 @default.
• W4387641229 cites W3183394461 @default.
• W4387641229 cites W4292616398 @default.
• W4387641229 cites W4293176435 @default.
• W4387641229 cites W4313594445 @default.
• W4387641229 cites W4327969917 @default.
• W4387641229 doi "https://doi.org/10.1016/j.jbo.2023.100507" @default.
• W4387641229 hasPublicationYear "2023" @default.
• W4387641229 type Work @default.
• W4387641229 citedByCount "0" @default.
• W4387641229 crossrefType "journal-article" @default.
• W4387641229 hasAuthorship W4387641229A5033557427 @default.
• W4387641229 hasAuthorship W4387641229A5044696716 @default.
• W4387641229 hasAuthorship W4387641229A5059457931 @default.
• W4387641229 hasAuthorship W4387641229A5073766586 @default.
• W4387641229 hasAuthorship W4387641229A5089822117 @default.
• W4387641229 hasBestOaLocation W43876412291 @default.
• W4387641229 hasConcept C120665830 @default.
• W4387641229 hasConcept C121332964 @default.
• W4387641229 hasConcept C121608353 @default.
• W4387641229 hasConcept C126322002 @default.
• W4387641229 hasConcept C143998085 @default.
• W4387641229 hasConcept C2777783956 @default.
• W4387641229 hasConcept C2779013556 @default.
• W4387641229 hasConcept C2779134260 @default.
• W4387641229 hasConcept C50382708 @default.
• W4387641229 hasConcept C61511704 @default.
• W4387641229 hasConcept C71924100 @default.
• W4387641229 hasConcept C72563966 @default.
• W4387641229 hasConceptScore W4387641229C120665830 @default.
• W4387641229 hasConceptScore W4387641229C121332964 @default.
• W4387641229 hasConceptScore W4387641229C121608353 @default.
• W4387641229 hasConceptScore W4387641229C126322002 @default.
• W4387641229 hasConceptScore W4387641229C143998085 @default.
• W4387641229 hasConceptScore W4387641229C2777783956 @default.
• W4387641229 hasConceptScore W4387641229C2779013556 @default.
• W4387641229 hasConceptScore W4387641229C2779134260 @default.
• W4387641229 hasConceptScore W4387641229C50382708 @default.
• W4387641229 hasConceptScore W4387641229C61511704 @default.
• W4387641229 hasConceptScore W4387641229C71924100 @default.
• W4387641229 hasConceptScore W4387641229C72563966 @default.
• W4387641229 hasLocation W43876412291 @default.
• W4387641229 hasOpenAccess W4387641229 @default.
• W4387641229 hasPrimaryLocation W43876412291 @default.
• W4387641229 hasRelatedWork W1501205893 @default.
• W4387641229 hasRelatedWork W2036989460 @default.
• W4387641229 hasRelatedWork W2057334354 @default.
• W4387641229 hasRelatedWork W2100632149 @default.
• W4387641229 hasRelatedWork W2363171232 @default.
• W4387641229 hasRelatedWork W2365507823 @default.
• W4387641229 hasRelatedWork W2744105963 @default.
• W4387641229 hasRelatedWork W3160437261 @default.
• W4387641229 hasRelatedWork W4254256614 @default.
• W4387641229 hasRelatedWork W4298087892 @default.
• W4387641229 hasVolume "43" @default.
• W4387641229 isParatext "false" @default.
• W4387641229 isRetracted "false" @default.
• W4387641229 workType "article" @default.